Economics of antiemetics in anesthesia

Current Opinion in Anaesthesiology

Volumn 14, Issue 5, 2001, Pages 563-567

  Watcha, Mehernoor F ^a,c   White, Paul F ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; DOLASETRON MESILATE; DROPERIDOL; METOCLOPRAMIDE; ONDANSETRON; PROPOFOL; SEROTONIN 3 ANTAGONIST; STEROID;

ANESTHESIA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; PATIENT SATISFACTION; POSTOPERATIVE NAUSEA; POSTOPERATIVE VOMITING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY;

EID: 0034786486     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200110000-00018     Document Type: Review

References (25)

1. The 'big little problem' of postoperative nausea and vomiting: Do we know the answer yet?
2. The big 'little problem'
3. Surrogate outcomes: Meaningful not
4. Postoperative nausea and vomiting: Prophylaxis versus treatment
5. Postoperative nausea and vomiting: Its etiology, treatment, and prevention
6. A rational approach to the control of postoperative nausea and vomiting: Evidence from systematic reviews. Part I. Efficacy and harm of antiemetic interventions, and methodological issues
7. How to use evidence-based medicine in anaesthesiology
8. Systematic reviews: Synthesis of best evidence for clinical decisions
9. Has the use of meta-analysis enhanced our understanding of therapies for postoperative nausea and vomiting?
10. Factors contributing to a prolonged stay after ambulatory surgery
11. Postoperative nausea and vomiting after discharge from outpatient surgery centers
12. Economics of anesthetic practice
13. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting
14. How much are patients willing to pay to avoid postoperative nausea and vomiting?
15. Antiemetic prophylaxis does not improve outcomes after outpatient surgery when compared to symptomatic treatment
16. Safety and efficacy of prophylactic ondansetron in patients undergoing radical mastectomy
17. Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: A meta-analysis
18. A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures
19. A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis
20. Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery
21. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol or placebo
22. Cost-effectiveness of prophylactic dolasetron or droperidol vs rescue therapy in the prevention of PONV in ambulatory gynecologic surgery
23. A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting
24. Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: A randomized, double-blind, placebo-controlled multicenter trial
25. The cost-effective management of postoperative nausea and vomiting